No qualifying author-owned investment thesis was confirmed in this post.
The author explicitly states they have no position in HIMS and frames the text as a question to others rather than expressing their own directional investment judgment.
Comments9
▶ Full Post Text
Vance Frost | Clinical Ops Analyst | 20 yrs clinical
CEO controls \~90% of voting power via super-voting Class V shares. HIMS built a real cash-pay subscription platform. Then it stepped into the one lane where "scale first, compliance later" doesn't fly.
Two businesses, one ticker:
1. The boring one that works: hair/ED/derm/mental health subscriptions.
2. The risky one: mass-marketed compounded GLP-1s pushed through a national funnel.
Why the GLP-1 lane got ugly:
* Feb 21, 2025: FDA said the semaglutide injection shortage was resolved.
* Sep 2025: FDA warning letter (dba Hers): marketing implying compounded semaglutide was the same as FDA-approved product = false/misleading; misbranding language.
* Feb 2026: FDA/HHS signaled enforcement posture; Reuters reported HHS said it would refer the matter to DOJ (civil or criminal exposure possible).
* Feb 9, 2026: Novo Nordisk filed a patent suit (reported), seeking to stop sales and pursue damages.
Balance sheet reality: Liquidity \~$1.1B (as stated in shareholder letter). Convertible notes: \~$1.0B principal due 2030 (fair value \~$1.12B as of Sep 30, 2025 per 10-Q). If the stock stays far below conversion, that's just debt.
Bottom line: The platform is real. But if your growth engine lives inside the enforcement line around mass marketing non-approved compounded GLP-1s, that revenue is conditional. Not durable.
What's your read... is the non-GLP-1 business strong enough to carry HIMS through this, or does the regulatory/legal overhang poison the whole ticker?
Disclosure: No position in HIMS. Not investment advice. Not medical or legal advice. Sources: SEC filings, FDA publications, and Reuters reporting on related regulatory/legal actions.